Introduction
============

Malignant pheochromocytoma and paraganglioma (PCC/PGL) comprise approximately 10--20% of all pheochromocytomas and paragangliomas ([@bib1]). According to the World Health Organization classification, the only accepted criterion for diagnosis of malignant PCC/PGL is the presence of metastases in the non-chromaffin areas ([@bib2]).

Metastases in patients with PCC/PGL are commonly diagnosed by anatomical imaging and/or functional imaging ([@bib3], [@bib4]). The latter includes ^123^I-metaiodobenzyl guanidine (^123^I-MIBG), ^18^F-flurodeoxyglucose positron emission tomography (^18^F-FDG PET/CT), ^18^F-flurodopamine PET (^18^F-FDA PET/CT), ^18^F-flurodopa PET (^18^F-FDOPA PET/CT) and ^68^Ga-DOTATATE PET/CT ([@bib3], [@bib4]). As compared to anatomical imaging and ^123^I-MIBG, ^18^F-FDG PET/CT has been proven to be more sensitive in diagnosing metastases ([@bib5], [@bib6], [@bib7], [@bib8]). However, ^68^Ga-DOTATATE PET/CT has proven to be a superior modality as compared to ^18^F-FDG PET/CT in the evaluation of SDHx-associated malignant PCC/PGL ([@bib3]).

Majority of the malignant PCCs/PGLs are initially diagnosed as benign tumours but subsequently present with widespread metastasis ([@bib9]). Small series and case reports have tried to analyse the clinical predictors for malignancy and have suggested size (greater than 5 cm), location (sympathetic PGL) of the primary tumour, tumour necrosis, non-secretory status and dopamine secretion as clinical predictors of metastatic disease in PCC/PGL ([@bib10], [@bib11], [@bib12], [@bib13], [@bib14]). Multiple population studies have suggested *SDHB* germline mutations as an important genetic predictor for metastasis, aggressiveness and poor outcome ([@bib15]). Histopathologic features like PASS score and Ki67 have also been suggested to predict malignancy ([@bib14], [@bib16]). However, none of the clinical, biochemical, radiological and histopathological predictors for malignancy has been largely proven successful; probably due to the rarity of the disease and paucity of data. Hence, we analysed data from our PCC/PGL cohort to identify the potential clinical predictors for malignancy in PCC/PGL.

Materials and methods
=====================

This retrospective study was conducted at a tertiary health care centre, which caters to Central and Western India. A written informed consent was obtained from all participants, and the study was approved by the institutional ethics committee. The study included 142 patients (M: 66, F: 76) with PCC/PGL registered at our centre between 2000 and 2015. Of these, 10 patients (*n* = 2 malignant) were referred for genetic analysis from other centres where they were managed, whereas the rest were managed at our institute. Data were obtained by retrospective record analysis of the participants. Metastasis was defined as the presence of tumour cells at sites that normally lack chromaffin tissue, and the metastatic lesions were proven either by histopathology or the presence of persistently elevated catecholamine biochemistry together with concurring functional imaging findings and previous history of PCC/PGL.

Preoperatively, 24-h urinary concentrations of vanillylmandelic acid (VMA) was initially performed till the year 2008 (*n* = 49) followed by plasma free normetanephrine and metanephrine since 2009 (*n* = 101). Tumours were localised by computed tomography (CT) and/or magnetic resonance imaging (MRI). In addition, ^131^I-MIBG scans were performed in majority of the patients (*n* = 110, 92 benign tumours and 18 malignant tumours), whereas ^18^F-FDG PET scanning was performed in 75 (60 benign tumours; 15 malignant tumours) patients. Two experienced laparoscopic surgeons operated on majority of the patients. Selection of surgical approach was according to the discretion of the operating surgeon. The cases with evidence of metastases at diagnosis (*n* = 13) underwent open surgical approach (*n* = 9 and *n* = 4 deferred surgery), whereas the remaining cases who developed metastases on follow-up (*n* = 7) had undergone laparoscopic excision (*n* = 5) and open excision (*n* = 2; one with a paraganglioma and one with PCC with size of 22 cm) of the primary tumour.

Genetic testing (*n* = 139) for five susceptibility genes (*VHL*, *RET*, *SDHB*, *SDHC* and *SDHD*) was performed using polymerase chain reaction and Sanger sequencing for identifying mutations and multiplex ligation-dependent probe amplification (MLPA) for large deletions. Postoperative follow-up included annual blood pressure and biochemical monitoring. Postoperatively, mapping with imaging was done if biochemistry was elevated or if tumour was preoperatively non-secretory.

Statistical analysis was performed using SPSS software, version 20.0 (SPSS). Chi-square test and the Mann--Whitney *U* test were used for the comparison of characteristics between benign and malignant PCC/PGL. Cut-off values for tumour size were calculated by receiver-operating characteristic (ROC). A *P* value of \<0.05 was considered significant. Linear regression analysis was done to identify the predictors of malignancy.

Results
=======

Patient demographics
--------------------

The study group comprised 142 patients (males: 66; females: 76). Of these, 96 had PCC, 28 had sPGLs, seven had multifocal disease (PCC + sPGL) and 11 had HNPGL. The mean age at diagnosis of the overall study population was 35 years (range, 6--75 years). Median duration of follow-up of the study cohort was 5.2 years (range: 6 months to 15 years).

Twenty patients (10 males and 10 females) were diagnosed with malignant PCC/PGL. Thirteen patients (65%) showed evidence of metastases at diagnosis and seven (35%) patients developed metachronous metastases after a median follow-up period of 17.5 months (range: 12--48 months). Synchronous metastases were common in bones, lungs and liver, whereas in patients with metachronous metastases, apart from bones, lungs and liver, five patients had local bed recurrence.

Radiology (CT-neck to pelvis) detected metastases in 55% (11/20) patients. It had sensitivity of 38.46% (5/13) for synchronous metastases (dorsal vertebrae: 3, lungs: 2) and 85.7% (6/7) for metachronous metastases (liver: 2, dorsal vertebra: 1 and lung nodules: 3). ^131^I-MIBG detected metastases in 27.78% (5/18). ^131^I-MIBG had sensitivity of 16.67% (2/12) for synchronous metastases (skull: 1, humerus and sacrum: 1) and 50% (3/6) for metachronous metastases (lung: 1, liver: 1 and humerus: 1). ^18^F-FDG PET/CT detected metastases in 100% (15/15). ^18^F-FDG PET/CT had 100% sensitivity for both synchronous as well as metachronous metastases. It performed well for both skeletal as well as soft tissue metastases. Management, follow-up and outcome of patients with malignant PCC/PGL are summarised in [Table 1](#tbl1){ref-type="table"}. Better detection of metastases with ^18^F-FDG PET/CT than CT and ^131^I-MIBG is depicted in [Fig. 1](#fig1){ref-type="fig"}, whereas [Fig. 2](#fig2){ref-type="fig"} depicts the performance of ^18^F-FDG PET/CT compared to CT and ^131^I-MIBG in a patient with benign unilateral PCC. Figure 1Case 11: 35/F, abdominal sPGL. (A) CT scan showing sPGL; (B) MIBG positive only in the primary; (C) positive FDG PET in primary and skeletal metastasis; (D) on follow-up, MIBG did not detect any lesions, but FDG detected multiple metastases. Figure 2Benign right PCC. (A) CT showing primary tumour; (B) MIBG showing uptake in primary; (C) FDG PET showing uptake only in primary. Table 1Description of clinical characteristics, mode of diagnosis, management and outcome of individual patients with malignant PCC/PGL.**Detection of metastases on imagingSex/age** (years)**LocationPrimary tumour size** (cm)**Secretory statusSite of metastasisTime to metastasis** (months)CT scanIMIBG18F FDG PET/CT**GeneticsManagement**M/39Unilateral; PCC10NormetanephrineLung nodules; vertebral metastases36Lung nodules; vertebral metastasesLung nodulesNANegativeAdvised MIBG therapy but lost to follow-upM/14Unilateral; PCC3NormetanephrineLiver; lymph nodes48NilLiver noduleMultiple liver metastasesNegative4 cycles of CVD chemotherapy and 3 cycles of MIBG therapy (1 curie); static diseaseF/28Abdominal; sPGL14Non-secretoryMultiple skeletal metastasesAt diagnosisNilMetastases in the sacrum and right humerusMultiple vertebral metastases, right clavicle, right humerus, sacrum and ribsNegativeDeferred surgery; no progression; no symptomsM/33Unilateral; HNPGL8.1Non-secretoryMultiple skeletal metastases; lung nodules; liver; posterior chest wallAt diagnosisNilNilMultiple skeletal metastases lungs posterior chest wall; liverNegativeEBRT for the primary tumour; CVD chemotherapy 2 cycles; lost to follow-upF/14Abdominal; sPGL6.4NormetanephrineLung nodule; multiple skeletal metastases; lymph nodes48Lung noduleSingle skeletal metastasis: humerusLung nodule; axillary lymph nodes; multiple skeletal sitesNegativeMetastatectomy of lung nodule; 3 cycles of PRRT; static disease; no progressionF/50Thoracic sPGL + abdominal sPGL9.6NormetanephrineLung nodulesAt diagnosisLung nodulesNilMultiple lung nodulesNegativeEBRT to primary tumour; 2 cycles of MIBG therapy; static disease; no progressionF/45Unilateral; PCC5.8NormetanephrineLungsAt diagnosisLung nodulesNilMultiple lung nodulesNegativeDeferred treatment; lost to follow-upF/43Bilateral PCC + abdominal sPGL7.2MetanephrineLiver; metastases36Liver nodulesnilLiver; multiple peritoneal metastases*RET* c.1901G\>ASuccumbed before treatment for metastasesM/30Unilateral; PCC8.7NormetanephrineLung nodules; peritoneal deposits24Lung nodulesNilMultiple lung nodules; multiple peritoneal metastasesNegative4 cycles of MIBG therapy; no progressionF/47Unilateral; PCC10Non-secretoryLungs; multiple skeletal metastasesAt diagnosisNilSingle skull metastasisLung nodules; skull and pelvic metastasesNegativePlanned MIBG therapyF/35Abdominal; sPGL9.4NormetanephrineLiver; bonesAt diagnosisNilNilLiver nodule; multiple skeletal metastasesNegativeSurgical excision of local bed recurrence; succumbed before treatment for metastasesM/45Unilateral; PCC5.8NormetanephrineVertebral metastases12Vertebral metastasisNilNANegativePlanned EBRT for vertebral metastases; lost to follow-upM/55Unilateral; PCC22Non-secretoryMalignant pleural effusion; liver24Malignant pleural effusion; multiple liver nodulesNANANegativeSuccumbed before therapy of the metastasesM/72Unilateral; PCC9NormetanephrineMultiple lung nodulesAt diagnosisNilNilMultiple lung nodulesNegativeRefused treatment; lost to follow-upF/49Unilateral; PCC4NAMultiple vertebral metastasesAt diagnosisVertebral metastasisNilNANAMIBG therapy one cycle; planned further cycles of MIBG; pain reliefF/40Bilateral; HNPGL4.7Non-secretoryMultiple vertebralAt diagnosisNilNilTwo vertebral metastasesNegativeEBRT given to both primary tumour as well as vertebral metastases; no new lesions; no increase in size of primaryM/40Abdominal; sPGL6.1NormetanephrineMultiple skeletal metastasesAt diagnosisVertebral metastasisNilMultiple skeletal metastasesNABisphosphonate therapy for skeletal metastases; planned EBRTM/27Abdominal; sPGL5.8NormetanephrineVertebral metastasesAt diagnosisVertebral metastasisNilNA*SDHB* c.251A\>CLost to follow-upM/36Abdominal; sPGL7.5NALiver; bonesAt diagnosisNilNilLiver; vertebral and long bones*SDHB* c286 + 1G\>ANo treatment for metastases; yet to follow-upF/43Unilateral; PCC10.1NormetaneprineAbdominal lymph nodesAt diagnosisNilNARegional lymph nodesNAOperated with clearance of regional lymph nodes; no new lesions[^1]

The baseline characteristics of benign and malignant PCC/PGL are summarised in [Table 2](#tbl2){ref-type="table"}. In the benign group, 31.2% (38/122) had a symptomatic presentation compared to 70% (14/20) in the malignant group (*P* = 0.002). Familial/syndromic association (10% (2/20) vs 7.4% (9/122), *P* = 0.65), normetanephrine-secreting tumours (12/18 (66.67%) vs 42/83 (50.6%), *P* = 0.29) and non-secretory tumours (5/18 (22.2%) vs 15/83 (18.07%), *P* = 0.34) were not significantly different between the malignant and benign groups, whereas metanephrine-secreting tumours (1/18 (5.55%) vs 26/83 (31.3%), *P* = 0.037) were significantly less in the malignant group. Table 2Comparison of clinical characteristics and germline mutations between patients with benign and malignant PCC/PGL.**Benign** (*n* = 122)**Malignant** (*n* = 20)***P* Value**Age (years)34.9 ± 14.439.3 ± 13.40.65Sex (M:F)56: 6610:100.8Symptomatic presentation38/122 (31.2%)14/20 (70%)0.002Primary tumour size (cm)5.7 ± 2.38.3 ± 4.10.0001Range2 to 14 cm3 to 22 cmAdrenal PCC86/122 (70.5%)10/20 (50%)0.07sPGL21/122(17.2%)7/20(35%)0.07HNPGL9/122 (7.4%)2/20 (10%)0.65Multifocal tumours6/122 (4.9%)1 /20 (5.0%)1BiochemistryMetanephrine secreting26/83 (31.3%)1/18 (5.55%)0.037Normetanephrine secreting42/83 (50.6%)12/18 (66.67%)0.29Non-secretory15/83 (18.07%)5/18 (22.2%)0.25*SDHB* germline mutations6/122 (4.9%)2/17 (11.8%)0.081[^2][^3]

Ten (10.4%) of the 96 patients with PCCs had metastases; five of these had metachronous metastases. Of the patients with sPGLs, seven patients (25%) had metastases, of whom one had metachronous metastases. Two patients (18.2%) with HNPGL had metastases, both at the diagnosis of primary tumour. One of the seven patients with multifocal disease had metastases on follow-up. Proportion of malignancy was significantly higher in patients with sPGL than those with PCC (10.4% vs 25%, *P* = 0.0048). However, the frequency of PCC, sPGL, HNPGL or multifocal tumours did not differ between malignant and benign groups ([Table 2](#tbl2){ref-type="table"}). Primary tumours in malignant group were significantly larger (8.3 ± 4.1 cm, range: 3--22 cm) than benign tumours (5.7 ± 2.3 cm, range: 2--14 cm, *P* = 0.0001). On receiver-operative characteristic curve analysis, cut-off of 5.7 cm had the best accuracy to identify malignant tumours (sensitivity: 80%; specificity: 59%).

We have recently reported the prevalence of germline mutations in 150 PCC/PGL patients from eight different centres from India ([@bib17]). One hundred and twenty patients from our institute included in that study are also part of the present cohort. In the metastatic group, 17 patients underwent genetic testing with three patients having positive germline mutations ((17.6%); *SDHB*: 2, *RET*: 1). In the benign group, 122 patients underwent genetic testing with genetic yield of 34.4% (42/122; *VHL*: 23, *RET*: 9, *SDHB*: 6, *SDHD*: 2, *SDHC*: 0 and NF1: 2). Prevalence of metastases was numerically higher in patients with germline mutations in *SDHB* (2/8, 25%) as compared to other mutation groups and mutation-negative group (14/94, 14.9%).

On linear regression analysis, including age, sex, tumour size, metanephrine secretion and presence of at least one extra-adrenal tumour as variables, only tumour size (*P* = 0.003) and lack of metanephrine elevation (*P* = 0.013) were the independent predictors of malignancy. When biochemistry was excluded from the analysis, tumour size (*P* \< 0.001) and presence of at least one extra-adrenal tumour were identified as independent predictors of malignancy (*P* = 0.013).

Discussion
==========

This is the first study that describes the prevalence, diagnostic sensitivities of commonly used anatomical and functional imaging methods and predictors of malignancy in Indian patients with malignant PCC/PGL. The prevalence of malignancy among our 142 patients with PCC/PGL was 14.08%, which is similar to that of previous reports from the rest of the world ([@bib18], [@bib19], [@bib20]). Majority of the malignant PCCs/PGLs usually present as apparently benign tumours without metastases at initial presentation ([@bib9]). In contrast, almost 2/3rd of our malignant PCC/PGL had metastases at initial presentation. Higher prevalence of metastases at initial presentation could be due to late presentation. Another reason for this phenomenon could be frequent testing at diagnosis of all our PCC/PGL patients with ^18^F-FDG PET/CT. On the other hand, shorter duration of follow-up and substantial rate of incomplete follow-up might have contributed for the low prevalence of metachronous metastases. The most frequent sites for metastases are lymph nodes, the skeleton, liver and lungs, which were also observed in our study ([@bib15]).

^18^F-FDG PET/CT had the best (100%) sensitivity for both skeletal and soft tissue metastases when compared to anatomical imaging (CT-neck to pelvis) (55%) and MIBG (27.78%). Superiority of ^18^F-FDG PET/CT over anatomical imaging and MIBG has been demonstrated in most of the other studies ([@bib5], [@bib6], [@bib7], [@bib8]). Sensitivities of anatomical imaging and ^18^F-FDG PET/CT in our study are similar to the previous reports. Poor performance of MIBG in our study is striking and is probably due to the use of ^131^I isotope that could not be coupled with SPECT. Additional reason for the poor sensitivity (16.67%) to diagnose synchronous metastases may be the uptake of most of the tracer by the large primary tumour. ^18^F-FDA PET/CT, ^18^F-FDG PET/CT and ^68^Ga-DOTATATE PET/CT are the recommended first-line functional imaging techniques for the diagnosis of metastases in PCC/PGL tumours; however, only the latter two are presently available in India ([@bib3], [@bib4]). Due to the relatively limited availability of ^68^Ga-DOTATATE PET/CT in India, ^18^F-FDG PET/CT hence becomes the first choice to detect metastases in Indian PCC/PGL patients ([@bib21]).

Many authors have attempted to find the predictors of malignancy in PCC/PGL, but no scoring system has been proven reliable ([@bib22]). Age at diagnosis, gender or familial/syndromic presentation did not correlate with the presence of metastases. However, malignant tumours were commonly symptomatic as compared to their benign counterparts as reported from Korea, in which persistence or increase of symptoms was observed with progression of metastases ([@bib23]).

In our study, metastatic PCC/PGL had significantly larger primary tumours than the benign ones. Tumour size was the strongest predictor of malignancy. Most of the previous studies have reported similar observations ([@bib11], [@bib13], [@bib24], [@bib25], [@bib26]). In contrast, one study reported no significant difference in the primary tumour size between malignant and benign tumours ([@bib27]). There is no clear cut-off of primary tumour size that distinguishes benign from malignant lesions. In our study, a cut-off of 5.7 cm provided the best accuracy (sensitivity: 80%; specificity: 59%). Among the 20% patients who had tumour size \<5.7 cm and evidence of metastases, three had PCC, one had HNPGL, whereas none had sPGL. Smallest tumour diameter in our study was 3 cm, which is similar to previous reports ([@bib14]). These findings suggest that even smaller tumours cannot be exempted from regular follow-up and careful vigilance.

Metanephrine-secreting tumours were rarely malignant, and this secretory status was an independent negative predictor of malignancy in our cohort. Less frequent secretion of metanephrine in malignant PCC/PGL may be due to the downregulation of phenyl­alanine-N-methyl transferase (PNMT) in dedifferentiated tumours and lack of metanephrine secretion by extradrenal tumours ([@bib14], [@bib28]). In contrast, one study has reported high metanephrine secretion as a predictor of malignancy ([@bib26]). Isolated or co-secretion of dopamine has been reported to be a marker of malignancy, but our patients were not routinely evaluated for dopamine secretory status ([@bib12], [@bib29], [@bib30]).

In our study, malignancy was more frequent among sPGL (25%) than PCC (10.4%) (*P* = 0.048). Similar observation has been noted in most of the previous studies ([@bib12], [@bib26]). The presence of at least one extra-adrenal tumour was an independent predictor of malignancy when biochemistry was excluded from the analysis. It suggests that when fractionated metanephrines are not available, extra-adrenal location can be used to predict the malignancy risk. Higher prevalence of malignancy in sPGL may be due to relative immaturity of sympathetic ganglia as compared to the adrenal medulla or due to the plausible role of adrenal cortex in the prevention of malignant transformation in PCC ([@bib10]).

The absence of underlying germline mutations in five major susceptibility genes in almost 90% of malignant PCC/PGL suggests the role for different susceptibility genes in the malignant group. There is strong literature evidence to support the relationship between mutations in the *SDHB* gene and the presence of malignant tumours ([@bib15], [@bib18], [@bib19], [@bib20]). Although *SDHB* mutations were the most common among our malignant patients, it was not an independent predictor of malignancy.

Multiple studies have tried to analyse histological predictors of malignancy like necrosis, PASS score and Ki67 without any significant success ([@bib14], [@bib16], [@bib31]). However, in our study, detailed histopathological data on these parameters were not sufficient to include in the analysis.

The European Society of Endocrinology (ESE) recommends the preoperative evaluation for malignancy with ^18^F-FDG PET/CT in patients with paraganglioma, elevated serum 3-methoxytyramine levels in plasma or urine and germline *SDHB* mutations ([@bib32]). We suggest that patients with apparently benign tumours at initial presentation with tumour size \>5.7 cm and isolated normetanephrine secretion or non-secretory status also be considered for preoperative evaluation with ^18^F-FDG PET/CT. In the postoperative period, evaluation for malignancy should be considered if there is elevation of catecholamines or their metabolites; in non-secretory tumours with primary tumour size \> 5.7 cm, routine evaluation with ^18^F-FDG PET/CT may be undertaken at regular intervals after surgery. The ESE guidelines suggest life-long follow-up for large tumours and PGL (33). We recommend the same; however, in Indian set up where regular follow-up is most often not ensured, a minimum follow-up for at least initial two years should be ensured during which the chances of metastases are high. The study is limited by the retrospective design, lack of histopathology data, relatively small number of patients and shorter postoperative follow-up.

Conclusion
==========

Primary tumour size \>5.7 cm and/or lack of metanephrine secretory status independently predict malignancy. Patients with either of these features should be evaluated for possible malignancy not only at initial presentation but also during follow-up, especially in the early postoperative period. ^18^F-flurodeoxyglucose PET/CT has the best sensitivity, whereas ^131^I-metaiodobenzylguanidine has the least sensitivity for diagnosis of metastases.
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[^1]: CVD, cyclophosphamide, vincristine and dacarbazine; EBRT, external beam radiotherapy; MIBG, metaiodobenzyl guanidine; PRRT, peptide receptor based radiotherapy.

[^2]: Location of the primary tumour and malignancy: no statistical significance was found when proportion of malignant tumours was compared across different locations of primary tumour: PCC (10/96), sPGL (7/28), HNPGL (2/11), multifocal (1/7); *P* = 0.29.

[^3]: Comparison of malignancy in PCC (10/96) and sPGL (7/28): *P* = 0.048.
